ライフサイエンスコーパス: follicle-stimulating hormone

1 eptides derived from a proteolytic digest of follicle stimulating hormone.

2 cycle patterns or on elevated (>20 IU/liter) follicle-stimulating hormone.

3 but had no effect on luteinizing hormone or follicle-stimulating hormone.

4 volved in the response of gonadal tissues to follicle-stimulating hormone.

5 ls of testosterone, luteinizing hormone, and follicle-stimulating hormone.

6 ), androstenedione, luteinizing hormone, and follicle-stimulating hormone.

7 pin-Releasing Hormone (1114.3 +/- 112.6 ug), Follicle Stimulating Hormone (13.2 +/- 1.5 IU/L), Lutein

8 8 mIU/mL; normal range, 0.1-6.0 mIU/mL), and follicle-stimulating hormone (6.93 mIU/mL; normal range,

9 8 mIU/mL; normal range, 0.1-6.0 mIU/mL), and follicle-stimulating hormone (6.93 mIU/mL; normal range,

10 discovered that thyroid-stimulating hormone, follicle-stimulating hormone, adrenocorticotropic hormon

11 iandrosterone sulfate, insulin, glucagon, or follicle-stimulating hormone after baseline hormone valu

12 ed a unique distribution of N-glycans on the follicle-stimulating hormone alpha subunit.

13 and fshr-1, which encode the orthologues of follicle stimulating hormone and its putative G protein-

14 Following superovulation with recombinant follicle-stimulating hormone and administration of gonad

15 Furthermore, an increase in follicle-stimulating hormone and decreases in testostero

16 mice and was associated with decreased serum follicle-stimulating hormone and higher claudin-11 expre

17 Concomitantly, the levels of follicle-stimulating hormone and IL-6 are increased 70 a

18 male mice do not feminize, and the levels of follicle-stimulating hormone and IL-6 are inhibited.

19 ted with a decrease in the concentrations of follicle-stimulating hormone and luteinising hormone, an

20 ll explore in detail effects on secretion of follicle-stimulating hormone and luteinising hormone.

21 higher body mass index (P = .05), and lower follicle-stimulating hormone and luteinizing hormone (ea

22 We measured follicle-stimulating hormone and luteinizing hormone and

23 with abdominal UDT had an increase in serum follicle-stimulating hormone and luteinizing hormone and

24 Pituitary gonadotropins follicle-stimulating hormone and luteinizing hormone are

25 acterized by increasing dyssynchrony between follicle-stimulating hormone and luteinizing hormone in

26 fetime history of depression also had higher follicle-stimulating hormone and luteinizing hormone lev

27 The mean (SE) follicle-stimulating hormone and luteinizing hormone lev

28 ge in menopausal status, increased levels of follicle-stimulating hormone and luteinizing hormone, an

29 levels were elevated, as were the levels of follicle-stimulating hormone and luteinizing hormone.

30 We further found that WNT5a prevents follicle-stimulating hormone and luteinizing protein fro

31 >=60 years or aged <60 years if their serum follicle-stimulating hormone and oestradiol concentratio

32 hormone secretion and on pituitary hormone (follicle-stimulating hormone and prolactin), CgA, and Cg

33 iation into spermatozoa, whereas recombinant follicle-stimulating hormone and steroid hormones are in

34 re glycoprotein hormones that are related to follicle-stimulating hormone and thyroid-stimulating hor

35 imulatory actions of luteinizing hormone and follicle-stimulating hormone and to 17beta-estradiol and

36 Pituitary (luteinizing hormone and follicle-stimulating hormone) and uterine functions were

37 tosterone or estradiol, leutinizing hormone, follicle stimulating hormone, and prolactin were determi

38 Activin acts in the pituitary to stimulate follicle-stimulating hormone, and is antagonized by endo

39 one, and increased variability of estradiol, follicle-stimulating hormone, and luteinizing hormone ar

40 ned 12-month analysis evaluated E2, E1, E1S, follicle-stimulating hormone, and luteinizing hormone le

41 ns, gonadotropin-releasing hormone agonists, follicle-stimulating hormone, and luteinizing hormone.

42 the urinary forms of estrogen, progesterone, follicle-stimulating hormone, and luteinizing hormone.

43 ake, physical activity, luteinizing hormone, follicle-stimulating hormone, and progesterone.

44 estosterone, dehydroepiandrosterone sulfate, follicle-stimulating hormone, and sex hormone-binding gl

45 ome reaction as well as luteinizing hormone, follicle-stimulating hormone, and testosterone serum lev

46 ologic surgery, hormone replacement therapy, follicle-stimulating hormone, and vasomotor symptoms.

47 Follicle-stimulating hormone, anti-Mullerian hormone, an

48 1p14.1 SNP, rs11031006, in the region of the follicle-stimulating hormone B polypeptide (FSHB) gene s

49 ell as inhibin B dimers, necessary for local follicle-stimulating hormone beta regulation.

50 Within 2 h, follicle-stimulating hormone beta subunit (FSHbeta) mRNA

51 localizes to alpha-glycoprotein subunit- and follicle-stimulating hormone beta-positive cells of the

52 f pulses from the hypothalamus and regulates follicle-stimulating hormone beta-subunit (FSHbeta) gene

53 Two protein hormones (follicle-stimulating hormone beta-subunit and thyroid-st

54 ations with sex hormone-binding globulin and follicle-stimulating hormone (beta = -0.04, 95% confiden

55 Increased levels of follicle-stimulating hormone (beta = 0.20, 95% confidenc

56 and the gene was localized to within 3 cM of follicle-stimulating hormone, beta polypeptide in the mi

57 Follicle-stimulating hormone-beta (FSHbeta) expression i

58 we report that exoloop 3 of FSH-R constrains follicle-stimulating hormone binding to the exodomain.

59 Activin stimulates whereas inhibin blocks follicle-stimulating hormone biosynthesis and secretion

60 irculating levels of luteinizing hormone and follicle-stimulating hormone but apparently normal respo

61 d in granulosa cells of growing follicles by follicle-stimulating hormone, but the highest levels of

62 gonadotropin, human luteinizing hormone, and follicle stimulating hormone by surface plasmon resonanc

63 nce last menses or since hysterectomy with a follicle-stimulating hormone concentration of >=40 U/L)

64 ostic variables: age, body-mass index, basal follicle-stimulating hormone concentration, and the numb

65 rian reserve, as indicated by elevated serum follicle-stimulating hormone concentrations ( 10 IU/L),

66 for estradiol, the free estradiol index, or follicle-stimulating hormone concentrations.

67 its in testosterone, luteinizing hormone, or follicle-stimulating hormone concentrations.

68 Results for estradiol and follicle-stimulating hormone confirmed the results based

69 glycopeptides of equine and human pituitary follicle stimulating hormone (eFSH and hFSH) have been c

70 amples were assayed for luteinizing hormone, follicle-stimulating hormone, estradiol, and progesteron

71 t flashes, night sweats) and serum levels of follicle-stimulating hormone, estradiol, and sex hormone

72 corresponding serum luteinizing hormone and follicle-stimulating hormone fell progressively during t

73 mones from the hypothalamus, luteinizing and follicle stimulating hormones from the pituitary, and go

74 nadotropin hormones (luteinizing hormone and follicle-stimulating hormone) from the pituitary.

75 Follicle stimulating hormone (FSH) acts through receptor

76 treatment of male infertility is the use of follicle stimulating hormone (FSH) analogs which improve

77 ician use AI to help select starting dose of follicle stimulating hormone (FSH) and trigger injection

78 a have implicated the pituitary gonadotropin follicle stimulating hormone (FSH) as both a risk factor

79 Follicle stimulating hormone (FSH) is a member of the gl

80 Follicle stimulating hormone (FSH) is one of the importa

81 hormone (ACTH), luteinizing hormone (LH) and follicle stimulating hormone (FSH) is preserved.

82 Leydig cell hyperproliferation and increased follicle stimulating hormone (FSH) levels.

83 Treatment of cultured Sertoli cells with follicle stimulating hormone (FSH) significantly increas

84 Total follicle stimulating hormone (FSH) stimulation dosage an

85 Activation of protein kinase A (PKA) by follicle stimulating hormone (FSH) transduces the signal

86 fect on sperm count and concentration, serum follicle stimulating hormone (FSH), luteinizing hormone

87 gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH).

88 hormones, testosterone, androstenedione and follicle stimulating hormone (FSH).

89 land to release luteinizing hormone (LH) and follicle stimulating hormone (FSH).

90 ropic hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH).

91 lower estradiol, bioavailable estradiol, and follicle-stimulating hormone (FSH) (all p < 0.05) than w

92 Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) act on gonadal cells

93 ic protein-15 (BMP-15) can directly modulate follicle-stimulating hormone (FSH) action in rat granulo

94 Follicle-stimulating hormone (FSH) acts by binding to FS

95 Serum follicle-stimulating hormone (FSH) and E2 were measured

96 was applied to quantify the degree to which follicle-stimulating hormone (FSH) and estradiol levels

97 gulated at least in part by hormones such as follicle-stimulating hormone (FSH) and estrogen.

98 esumption of menses and serial monitoring of follicle-stimulating hormone (FSH) and inhibin A and B l

99 Although both the levels of follicle-stimulating hormone (FSH) and inhibin B are cor

100 an inhibitor of prostaglandin signaling and follicle-stimulating hormone (FSH) and luteinizing hormo

101 GnRH regulates the pituitary gonadotropin's follicle-stimulating hormone (FSH) and luteinizing hormo

102 Follicle-stimulating hormone (FSH) and luteinizing hormo

103 Undetectable or low levels of serum follicle-stimulating hormone (FSH) and luteinizing hormo

104 ght have an acute effect on the secretion of follicle-stimulating hormone (FSH) and luteinizing hormo

105 Leptin produced a dose-related increase in follicle-stimulating hormone (FSH) and luteinizing hormo

106 GnRH stimulates follicle-stimulating hormone (FSH) and luteinizing hormo

107 ted by two distinct pituitary gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormo

108 rocesses are controlled by the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormo

109 ole in reproductive physiology by regulating follicle-stimulating hormone (FSH) and luteinizing hormo

110 ols the release of the gonadotropic hormones follicle-stimulating hormone (FSH) and luteinizing hormo

111 ynthesis and secretion of the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormo

112 one, testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and sex hormone-bindi

113 Follicle-stimulating hormone (FSH) and syt-9 are highly

114 is Review, we briefly outline the roles that follicle-stimulating hormone (FSH) and testosterone play

115 Follicle-stimulating hormone (FSH) and the EGF-like pept

116 Multiple interactions exist between human follicle-stimulating hormone (FSH) and the N-terminal ho

117 Structure-function studies of follicle-stimulating hormone (FSH) and the other glycopr

118 opausal levels of the pituitary gonadotropin follicle-stimulating hormone (FSH) are strongly associat

119 es over the past decade have established the follicle-stimulating hormone (FSH) as an actionable targ

120 Macroheterogeneity in follicle-stimulating hormone (FSH) beta-subunit N-glycos

121 We have also shown that follicle-stimulating hormone (FSH) can increase the expr

122 Follicle-stimulating hormone (FSH) comprises an alpha su

123 had a body-mass index of 19-35 kg/m(2) and a follicle-stimulating hormone (FSH) concentration of 3.0-

124 teinizing hormone (LH) secretion and that of follicle-stimulating hormone (FSH) could be valuable in

125 Follicle-stimulating hormone (FSH) glycosylation is regu

126 Among its extragonadal effects, follicle-stimulating hormone (FSH) has an impact on body

127 nses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal

128 ts the beta-subunit of the pituitary hormone follicle-stimulating hormone (Fsh) increases bone mass i

129 We previously showed that follicle-stimulating hormone (FSH) induces the expressio

130 e both suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) initially, a rebound

131 Follicle-stimulating hormone (FSH) is an essential regul

132 and c) test whether treatment with exogenous follicle-stimulating hormone (FSH) is capable of rescuin

133 Follicle-stimulating hormone (FSH) is central to reprodu

134 Follicle-stimulating hormone (FSH) is in the family of p

135 Defined progesterone and follicle-stimulating hormone (FSH) levels were considere

136 ed whether all-trans-retinoic acid (tRA) and follicle-stimulating hormone (FSH) modulate RARalpha rec

137 mvent this problem, a genetically engineered follicle-stimulating hormone (FSH) mutant protein was pr

138 stis by conjugating Adjudin to a recombinant follicle-stimulating hormone (FSH) mutant, which serves

139 Studies-Depression Scale [CES-D Scale]) and follicle-stimulating hormone (FSH) plasma levels of depr

140 way, based on evidence that the GPCR agonist follicle-stimulating hormone (FSH) promotes the protein

141 lenge experiments to identify regions in the follicle-stimulating hormone (FSH) receptor (FSHR) ECD t

142 Follitropin, or follicle-stimulating hormone (FSH) receptor (FSHR), is a

143 ceptors are highly conserved, we mutated the follicle-stimulating hormone (FSH) receptor at the corre

144 The human follicle-stimulating hormone (FSH) receptor consists of

145 mely, BMP-15 promotes GC mitosis, suppresses follicle-stimulating hormone (FSH) receptor expression,

146 ependent of transcription, androgens enhance follicle-stimulating hormone (FSH) receptor expression,

147 In adult humans, the follicle-stimulating hormone (FSH) receptor is expressed

148 ught to elucidate the mechanism by which the follicle-stimulating hormone (FSH) receptor signals to p

149 hormone (LH)/chorionic gonadotropin (CG) or follicle-stimulating hormone (FSH) receptor, that at lea

150 Inhibiting the action of follicle-stimulating hormone (FSH) reduces body fat, enh

151 Follicle-stimulating hormone (FSH) regulates follicular

152 there is a separate hypothalamic control of follicle-stimulating hormone (FSH) release distinct from

153 ine hormone that directly promotes pituitary follicle-stimulating hormone (FSH) synthesis and thereby

154 Regulation of follicle-stimulating hormone (FSH) synthesis is a centra

155 Although activins and inhibins regulate follicle-stimulating hormone (FSH) synthesis, no factor

156 ily protein hormones that suppress pituitary follicle-stimulating hormone (FSH) synthesis.

157 In mice, we previously showed that follicle-stimulating hormone (FSH), a gonadotropin that

158 Follicle-stimulating hormone (FSH), a key regulator of o

159 Follicle-stimulating hormone (FSH), a product of pituita

160 ycoprotein hormones, luteinizing hormone and follicle-stimulating hormone (FSH), act through their co

161 The gonadotropins, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and chorionic gonado

162 Baseline luteinizing hormone (LIT), follicle-stimulating hormone (FSH), and free-alpha-subun

163 serum level of antimullerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and ur

164 n reproduction depends on the gonadotropins, follicle-stimulating hormone (FSH), and luteinizing horm

165 ht to investigate the role of gonadotropins, follicle-stimulating hormone (FSH), and luteinizing horm

166 o direct the synthesis of the gonadotropins, follicle-stimulating hormone (FSH), and luteinizing horm

167 Measures of ovarian reserve were day-3 follicle-stimulating hormone (FSH), antral follicle coun

168 unction was assessed by serum measurement of follicle-stimulating hormone (FSH), estradiol, and anti-

169 es undergo exponential growth in response to follicle-stimulating hormone (FSH), largely as a result

170 Fos family members in response to hormones (follicle-stimulating hormone (FSH), luteinizing hormone

171 tary, this innervation was observed close to follicle-stimulating hormone (FSH), luteinizing hormone

172 e sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, fasting p

173 s 6-12 h after stimulation with forskolin or follicle-stimulating hormone (FSH), the major physiologi

174 iometry, and measurements of BNP, NT-proBNP, follicle-stimulating hormone (FSH), total testosterone,

175 Follicle-stimulating hormone (FSH), traditionally known

176 cells to proliferate normally in response to follicle-stimulating hormone (FSH), whereas mutant males

177 vels of estradiol in women are controlled by follicle-stimulating hormone (FSH), which regulates tran

178 progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), which were measured

179 phosphorylation, and thus, the expression of follicle-stimulating hormone (FSH)- and testosterone-ind

180 lial ovarian cancer nor its interaction with follicle-stimulating hormone (FSH)-driven proliferation

181 n, and importantly, the mitogenic effect was follicle-stimulating hormone (FSH)-independent.

182 ells (GCs) and produces a marked decrease in follicle-stimulating hormone (FSH)-induced progesterone

183 We sought to elucidate the role of AKT in follicle-stimulating hormone (FSH)-mediated granulosa ce

184 rized by amenorrhea and high serum levels of follicle-stimulating hormone (FSH).

185 y a ligand, epidermal growth factor (EGF) or follicle-stimulating hormone (FSH).

186 anulosa cells stimulated to differentiate by follicle-stimulating hormone (FSH).

187 double-null mice produce elevated levels of follicle-stimulating hormone (FSH).

188 beta-subunits of luteinizing hormone (LH) or follicle-stimulating hormone (FSH).

189 lls [expressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH)], with adrenocorticom

190 as the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] >/= 40 IU/L) after 1

191 omes included gonadal function recovery (via follicle-stimulating hormone [FSH] concentrations), conc

192 The beta subunit of follicle stimulating hormone (FSHB) is expressed specifi

193 ry pituitary hormones, growth hormone (gh1), follicle stimulating hormone (fshb), and thyroid stimula

194 alising behaviour, with key genes related to follicle stimulating hormone (FSHB), implantation (ESR1)

195 d that mice deficient in the beta-subunit of follicle-stimulating hormone (FSHbeta) are protected fro

196 pressing a glycoprotein hormone receptor for follicle-stimulating hormone (FSHR), CXC- (CXCR-2), and

197 g hormone measurements (menopause defined by follicle stimulating hormone >30 mIU/mL and oestradiol <

198 , greater than 3 months of amenorrhea, and a follicle-stimulating hormone > or = 30 MIU/mL at the 12-

199 enstrual periods and serum concentrations of follicle-stimulating hormone >25 IU/L), meeting criteria

200 human chorionic gonadotropin (hCG) and human follicle-stimulating hormone had shown that it was possi

201 agment derived from the beta-domain of human Follicle-Stimulating Hormone (hFSH) are described.

202 nic gonadotropin (hCG), luteinizing hormone, follicle-stimulating hormone (hFSH), and thyroid-stimula

203 een human choriogonadotropin (hCG) and human follicle-stimulating hormone (hFSH), but determinants of

204 and 651 enhance the internalization of human follicle-stimulating hormone (hFSH).

205 sary for embryonic development and pituitary follicle-stimulating hormone homeostasis, mice deficient

206 pausal status and in levels of estradiol and follicle-stimulating hormone in 2,659 women followed in

207 5+/-4.6 IU per liter (P<0.001), the level of follicle-stimulating hormone increased from 2.5+/-1.7 to

208 provide in vivo evidence demonstrating that follicle-stimulating hormone increases MLT content in ov

209 effects of recombinant BMP-4 and -7 on FSH (follicle-stimulating hormone)-induced rat granulosa cyto

210 family of small G-proteins is essential for follicle stimulating hormone-induced signaling events an

211 y acids (FFAs) in the follicular fluid since follicle-stimulating hormone induces and luteinizing hor

212 A greater follicle-stimulating hormone level predicted lower SBP a

213 Body and testicular weight, testosterone, follicle-stimulating hormone level, and luteinizing horm

214 vaginal dryness (LR+ range, 1.48-3.79), high follicle-stimulating hormone levels (LR+ 3.06; 95% CI, 2

215 Serum follicle-stimulating hormone levels in the adult animals

216 with heavier menstrual bleeding, and higher follicle-stimulating hormone levels were associated with

217 tography and tandem mass spectrometry assay; follicle-stimulating hormone levels were measured at bas

218 Serum-luteinizing and follicle-stimulating hormone levels were normal, with a

219 , evaluated using anti-Mullerian hormone and follicle-stimulating hormone levels, was similar in both

220 tory findings (insulin-like growth factor 1, follicle-stimulating hormone, luteinizing hormone, and t

221 ntify up to 269 genetic loci associated with follicle-stimulating hormone, luteinizing hormone, estra

222 mong pituitary tumors, 30% (7/23), mainly in follicle-stimulating hormone/luteinizing hormone-produci

223 (including human chorionic gonadotropin and follicle-stimulating hormone) may be used to preserve or

224 he transplantation in both patients by serum follicle-stimulating hormone measurements (patient A, 47

225 ment led to significant increases in CgB and follicle-stimulating hormone mRNAs in gonadotroph adenom

226 l Interview for DSM-IV, and plasma levels of follicle-stimulating hormone obtained at 3-6-month inter

227 sociated with a lower likelihood of elevated follicle-stimulating hormone (odds ratio (OR)=0.6, 95% c

228 before the FMP in the log rate of change of follicle-stimulating hormone (odds ratio, 0.65; 95% CI,

229 le development by attenuating the effects of follicle stimulating hormone on follicle growth and inhi

230 (-/-) cumulus cells do not respond to either follicle-stimulating hormone or IGF-I.

231 Serum levels of follicle-stimulating hormone (P=0.002) and luteinizing h

232 rmone release compared to KP10 and increased follicle-stimulating hormone plasma concentration.

233 adenomas, a gonadotroph luteinizing hormone/follicle-stimulating hormone-positive adenoma, exhibited

234 ed for individuals with a rapidly increasing follicle-stimulating hormone profile (P< or =.001) and a

235 icles, treatment with R-spondin2, similar to follicle stimulating hormone, promoted the development o

236 r ovarian stimulation with the letrozole and follicle-stimulating hormone protocol preserves fertilit

237 elical loops of luteinizing hormone receptor/follicle stimulating hormone receptor/thyroid stimulatin

238 The human follicle-stimulating hormone receptor (FSH-R) consists o

239 in reaction techniques for the evaluation of follicle-stimulating hormone receptor (FSHR) expression

240 The promoter for the rat follicle-stimulating hormone receptor (FSHR) gene contai

241 The luteinizing hormone receptor (LHR) and follicle-stimulating hormone receptor (FSHR) have an app

242 Follicle-stimulating hormone receptor (FSHR), a G-protei

243 les at the extracellular domain (ECD) of the follicle-stimulating hormone receptor (FSHR).

244 Human follicle-stimulating hormone receptor (hFSHR) belongs to

245 had a Sertoli cell appearance and expressed follicle-stimulating hormone receptor within the seminif

246 d the conserved serine in the LH (S277I) and follicle-stimulating hormone receptors (S273I) and obser

247 ot only are observed in regions that control follicle-stimulating hormone release but also are coloca

248 Additionally, A/C 46-78 decreased follicle-stimulating hormone release from the LbetaT2 ce

249 Follicle-stimulating hormone release was maximally inhib

250 er this peptide, known to selectively induce follicle-stimulating hormone release, is coexpressed in

251 Igf1r in primary follicles elicits defective follicle-stimulating hormone responsiveness blocking dev

252 e to TGF-beta with significant inhibition of follicle-stimulating hormone secretion at higher concent

253 entrations (10(-9) mol/L) and stimulation of follicle-stimulating hormone secretion at lower concentr

254 anscriptional activity and by suppression of follicle-stimulating hormone secretion by cultured anter

255 ding, activin transcriptional responses, and follicle-stimulating hormone secretion substantiates the

256 Increased luteinizing hormone relative to follicle-stimulating hormone secretion, insulin resistan

257 stradiol, progesterone, luteinizing hormone, follicle-stimulating hormone, sex hormone-binding globul

258 Although follicles responded to initial follicle-stimulating hormone stimulation and developed n

259 onized the inhibitory effects of BMP4 on the follicle-stimulating hormone stimulation of progesterone

260 ta superfamily, is an important modulator of follicle-stimulating hormone synthesis and secretion in

261 ne (Tam-IVF) or in combination with low-dose follicle-stimulating hormone (TamFSH-IVF) or letrozole 5

262 amples were assayed for levels of estradiol, follicle-stimulating hormone, testosterone, and dehydroe

263 s do not support the use of urinary or blood follicle-stimulating hormone tests or antimullerian horm

264 Ratios of follicle stimulating hormone to luteinizing hormone, a s

265 combinant JY-1 protein regulates function of follicle-stimulating hormone-treated ovarian granulosa c

266 y end point was POF, defined as at least one follicle-stimulating hormone value of > 40 IU/L after 2

267 onths, and/or oophorectomy, and/or increased follicle-stimulating hormone values for reproductive-age

268 ng for the aromatase and the receptor of the follicle stimulating hormone were higher in contaminated

269 eir plasma levels of luteinizing hormone and follicle stimulating hormone were inappropriately low.

270 diol, progesterone, luteinizing hormone, and follicle-stimulating hormone were measured in serum up t

271 diol, progesterone, luteinizing hormone, and follicle-stimulating hormone were measured up to 8 times

272 sing hormone (GnRH) agonists and recombinant follicle-stimulating hormone were studied prospectively.

273 (human leutinizing hormone) and hFSH (human follicle stimulating hormone) were > 1 microM and approx

274 ost of patients (93%) had abnormal values of follicle-stimulating hormone, whereas the number of pati